Videos

V Michael Holers, MD, discusses the creation of Rheumatology Lab in response to a pressing need within the clinical practice community to provide an easily accessible resource for physicians to guide patients to valuable information.

Robert Edwards, PhD, discusses how cognitive behavioral therapy effectively reduced pain catastrophizing and improved quality of life in patients with fibromyalgia.

Ruth Napier, PhD, discusses her study revealing the crucial role the biomarker Card9 plays in the pathogenesis of ankylosing spondylitis.

The approval of the intravenous formulation of secukinumab allows healthcare providers to better tailor treatment to their patients’ unique needs. 

In this MEDcast episode, Drs. Soloman, Sharobeem, and Mease discuss newer mechanisms of actions and emerging therapies in rheumatic diseases and tools that are becoming available to rheumatologists to practice precision medicine.

Nehad Soloman, MD, believes acknowledging the cultural and social dynamics impacting patients' healthcare decisions and establishing a personal connection with patients can help overcome initial barriers to care.

JB Boone, MD, explains the progress being made towards more personalized medicine in patients with rheumatoid arthritis, as well as the current challenges.

JB Boone, MD, explains PrismRA, a predictive tool designed to determine whether a patient will likely have an inadequate response to a TNF inhibitor.

In this MEDcast episode, Drs Soloman, Sharobeem, Boone and Feldman discuss the use of step therapy in rheumatoid arthritis, how step therapy was intended to be used, how it is actually used, and challenges and solutions to its use.

Jeffrey Sparks, MD, MMSc, discusses what rheumatologists need to know about treating challenging cases of rheumatoid arthritis as well as the risks and benefits of more aggressive treatment strategies.

Experts conclude their discussion emphasizing the importance of integrative care and how providers can improve outcomes for their patients with fibromyalgia (FM).

Experts highlight current challenges in their practice treating patients with fibromyalgia (FM).

Experts discuss how they personalize treatments for patients with fibromyalgia (FM) and the importance of improving sleep in their approach.

Experts discuss the limited combination therapy options for the treatment of fibromyalgia (FM) and how to inform patients of prospective outcomes.

Experts discuss their step therapy approaches for the treatment of fibromyalgia (FM).

Experts discuss the long-term safety and efficacy of agents used for the treatment of fibromyalgia (FM).

Experts discuss the FDA approved agents duloxetine and pregabalin for the treatment of fibromyalgia (FM).

Experts discuss the FDA approved agent milnacipran for the treatment of fibromyalgia (FM).

Experts offer their clinical experience discussing how they utilize off label drugs in the treatment of fibromyalgia (FM).

Experts offer their clinical experience with nonsteroidal anti-inflammatory drugs (NSAID) in the treatment of fibromyalgia (FM).

Experts discuss their therapeutic approach and key agents utilized in the treatment of fibromyalgia (FM).

Albert Roy, president of the Lupus Research Alliance, elaborates on recent initiatives designed to address the underrepresentation of minorities in lupus research.

Albert Roy, president of the Lupus Research Alliance, discusses the efforts his team are making to combat the underrepresentation of minorities in clinical trials as well as the scientific research profession.

Experts discuss treatment options for fibromyalgia (FM) and how they utilize integrative care with patients.

Experts discuss which providers often diagnose fibromyalgia (FM) and how the burden of care has changed in recent years.

Experts discuss common comorbidities for patients with fibromyalgia (FM).

Experts offer clinical experience on why fibromyalgia (FM) is challenging to diagnose and how they rule out other chronic pain disorders.

At the 12-month mark, response rate in patients with uncontrolled gout was significantly higher in those treated with pegloticase and concomitant methotrexate when compared with placebo.

Experts offer their clinical advice on what factors, outside of clinical therapies, may mitigate symptoms of fibromyalgia (FM).

Experts discuss the common characteristics of fibromyalgia (FM) and related symptoms.